Publications
October 26, 2022
Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in diffuse Large B Cell Lymphoma…
June 29, 2022
Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma
June 12, 2021
Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other Non-Hodgkin’s B-cell lymphomas –…
March 23, 2021
Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders
April 16, 2018
Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell…